Evidence map›Paper›PMID 42351915›Full record

ArticleBioengineering (Basel, Switzerland)2026

Keratin-Laden Bioink for Corneal Stroma Bioprinting.

Leon Balters, Stephan Reichl

Abstract read
In one paragraph

Article in Bioengineering (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Leon BaltersInstitute of Pharmaceutical Technology and Biopharmaceutics, Technische Universität Braunschweig, 38106 Braunschweig, Germany.ORCID 0009-0008-0256-9512
Stephan ReichlInstitute of Pharmaceutical Technology and Biopharmaceutics, Technische Universität Braunschweig, 38106 Braunschweig, Germany.ORCID 0000-0001-8344-9070

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Corneal blindness remains a major clinical challenge, yet donor grafts are scarce. Bioprinting has emerged in recent decades to potentially overcome donor shortage. In bioprinting, collagen is a common biomaterial. However, one alternative biomaterial, which has shown promising results in corneal tissue engineering, is keratin. Therefore, human hair keratin was investigated in this study as a bioink component for stroma bioprinting. Two keratin preparations, an aqueous extraction and an alkaline extraction, were incorporated into a methacrylated hyaluronic acid bioink and compared with a collagen methacrylated hyaluronic acid bioink. Corneal stroma-like constructs were printed by extrusion bioprinting and evaluated for optical transmission, biomechanical properties, cell compatibility and protein expression of collagen type I and alpha-smooth muscle actin over a four-week period. Two different cell types, immortalized corneal keratocytes and human corneal fibroblasts, were used. The alkaline keratin dialysate-supplemented bioink showed similar optical transparency and biomechanical properties to the collagen-supplemented bioink. Cell viability was high in all formulations. Protein expression of collagen type I and α-smooth muscle actin remained low in all bioinks. Human corneal fibroblasts appeared to be in a quiescent state and were unable to produce large amounts of collagen. This comparative study between collagen and keratin is a first step towards establishing keratins in bioprinting, leading to more complex bioinks.

Indexed as

bioprintingcollagencorneacorneal fibroblastshyaluronic acidkeratinkeratocytes

Identifiers

PMID42351915
PMCPMC13296209

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.